Current therapies in clinical trials of Parkinson's disease: A 2021 update

EM Prasad, SY Hung - Pharmaceuticals, 2021 - mdpi.com
Parkinson's disease (PD) is a progressive neurodegenerative disorder that currently has no
cure, but treatments are available to improve PD symptoms and maintain quality of life. In …

Data science, artificial intelligence, and machine learning: opportunities for laboratory medicine and the value of positive regulation

D Gruson, T Helleputte, P Rousseau, D Gruson - Clinical biochemistry, 2019 - Elsevier
Artificial intelligence (AI) and data science are rapidly developing in healthcare, as is their
translation into laboratory medicine. Our review article presents an overview of the data …

Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v. 3.0

L Heirendt, S Arreckx, T Pfau, SN Mendoza… - Nature protocols, 2019 - nature.com
Constraint-based reconstruction and analysis (COBRA) provides a molecular mechanistic
framework for integrative analysis of experimental molecular systems biology data and …

Personalized whole‐body models integrate metabolism, physiology, and the gut microbiome

I Thiele, S Sahoo, A Heinken, J Hertel… - Molecular systems …, 2020 - embopress.org
Comprehensive molecular‐level models of human metabolism have been generated on a
cellular level. However, models of whole‐body metabolism have not been established as …

Levodopa-induced dyskinesias in Parkinson's disease: An overview on pathophysiology, clinical manifestations, therapy management strategies and future directions

L di Biase, PM Pecoraro, SP Carbone… - Journal of clinical …, 2023 - mdpi.com
Since its first introduction, levodopa has become the cornerstone for the treatment of
Parkinson's disease and remains the leading therapeutic choice for motor control therapy so …

Personalized metabolic whole-body models for newborns and infants predict growth and biomarkers of inherited metabolic diseases

E Zaunseder, U Mütze, JG Okun, GF Hoffmann… - Cell Metabolism, 2024 - cell.com
Comprehensive whole-body models (WBMs) accounting for organ-specific dynamics have
been developed to simulate adult metabolism, but such models do not exist for infants. Here …

To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson's disease

C Rusch, R Flanagan, H Suh, I Subramanian - npj Parkinson's Disease, 2023 - nature.com
Administration of levodopa for Parkinson's disease (PD) has remained the most effective
therapy for symptom management despite being in use for over 50 years. Advancing …

[HTML][HTML] Advances in flux balance analysis by integrating machine learning and mechanism-based models

A Sahu, MA Blätke, JJ Szymański, N Töpfer - Computational and structural …, 2021 - Elsevier
The availability of multi-omics data sets and genome-scale metabolic models for various
organisms provide a platform for modeling and analyzing genotype-to-phenotype …

Parkinson's disease patients' short chain fatty acids production capacity after in vitro fecal fiber fermentation

F Baert, C Matthys, J Maselyne, C Van Poucke… - npj Parkinson's …, 2021 - nature.com
Animal models indicate that butyrate might reduce motor symptoms in Parkinson's disease.
Some dietary fibers are butyrogenic, but in Parkinson's disease patients their butyrate …

[HTML][HTML] Clinical implications of gastric complications on levodopa treatment in Parkinson's disease

RF Pfeiffer, SH Isaacson, R Pahwa - Parkinsonism & Related Disorders, 2020 - Elsevier
Disorders of the gastrointestinal (GI) tract are common and distressing nonmotor symptoms
of Parkinson's disease (PD) that can adversely affect levodopa absorption and lead to OFF …